Trial
NCT05926960
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
Merck Sharp & Dohme LLC
Condition
Melanoma
Intervention
encorafenib
Why stopped
Study terminated due to inability to recruit the target number of patients. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-09